SCHEMBL25710213

SCHEMBL25710213

CC(O)C(N)CSCC=O

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ METAP2 P50579 1/20 0.30
▸ METAP1 P53582 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18175928 0.87 — —
SCHEMBL25710427 0.78 — —
SCHEMBL2550728 0.72 — —
SCHEMBL24287227 0.69 — —
SCHEMBL13302739 0.69 — —
SCHEMBL24311674 0.68 NOS2 (0.33) —
SCHEMBL24311808 0.68 NOS2 (0.33) —
SCHEMBL14151192 0.67 — —
SCHEMBL20077224 0.67 KIF11 (0.38) —
SCHEMBL13740673 0.65 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183292-A1 IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2023-06-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183292-A1 IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 METAP2 2506/4885METAP1 1723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback